Early Worsening Heart Failure in Patients Admitted for Acute Heart Failure: Time Course, Hemodynamic Predictors, and Outcome

被引:54
作者
Torre-Amione, Guillermo [2 ]
Milo-Cotter, Olga [1 ]
Kaluski, Edo [3 ]
Perchenet, Loic [4 ]
Kobrin, Isaac [4 ]
Frey, Aline [4 ]
Rund, Michele M. [1 ]
Weatherley, Beth Davison [1 ]
Cotter, Gad [1 ]
机构
[1] Momentum Res Inc, Durham, NC 27707 USA
[2] Baylor Coll Med, Methodist Hosp, Winters Ctr Heart Failure Res, Houston, TX 77030 USA
[3] Univ Med & Dent New Jersey, Dept Cardiol, Cardiac Catheterizat Labs, Newark, NJ 07103 USA
[4] Actel Pharmaceut, Alchwil, Switzerland
关键词
Acute heart failure; CARDIAC POWER; RECEPTOR ANTAGONIST; MORTALITY; TEZOSENTAN;
D O I
10.1016/j.cardfail.2009.04.001
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: The most common outcome currently assessed in acute heart failure trials (AHF) is dyspnea improvement. Worsening hear failure (WHF) is a new outcome measure that incorporates failure to improve or recurrent symptoms of AHF requiring rescue intravenous therapy, mechanical circulatory or ventilatory support, or readmission because of AHF, occurring within 30 days of AHF admission. Methods and Results: Retrospective data analysis of 120 patients with AHF requiring hemodynamic monitoring who enrolled in the placebo arm of 2 prospective randomized studies. The incidence of WHF was 42% at 30 days from enrollment. Most WHF events occurred in-hospital during the first 7 days after admission (early WHF). Thirty-day readmission from AHF was an infrequent event in the present cohort (5.0%). The strongest hemodynamic predictors of WHF were cardiac power at baseline and its change during the initial 6 hours of monitoring. Other hemodynamic parameters associated with WHF events were blood pressure and its increase, cardiac output, and pulmonary wedge pressure change during the initial 6 hours of monitoring. WHF was found to be a strong predictor of 6-month mortality. Conclusions: WHF is a common morbid event clustered mostly during the first week of AHF admission and is associated with higher 6-month mortality. The hemodynamic measurements associated with WHF are similar to those predicting adverse outcome in AHF and cardiogenic shock (low cardiac power, higher pulmonary capillary wedge pressure, and vascular resistance), emphasizing the notion that early WHF should become an important AHF-specific outcome measure. (J Cardiac Fail 2009;15:639-644)
引用
收藏
页码:639 / 644
页数:6
相关论文
共 21 条
[1]
[Anonymous], 2003, HEART DIS STROK STAT
[2]
Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE [J].
Cleland, JGF ;
Freemantle, N ;
Coletta, AP ;
Clark, AL .
EUROPEAN JOURNAL OF HEART FAILURE, 2006, 8 (01) :105-110
[3]
The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe - Part 1: patient characteristics and diagnosis [J].
Cleland, JGF ;
Swedberg, K ;
Follath, F ;
Komajda, M ;
Cohen-Solal, A ;
Aguilar, JC ;
Dietz, R ;
Gavazzi, A ;
Hobbs, R ;
Korewicki, J ;
Madeira, HC ;
Moiseyev, VS ;
Preda, I ;
van Gilst, WH ;
Widimsky, J ;
Freemantle, N ;
Eastaugh, J ;
Mason, J .
EUROPEAN HEART JOURNAL, 2003, 24 (05) :442-463
[4]
A national survey of heart failure in French hospitals [J].
Cohen-Solal, A ;
Desnos, M ;
Delahaye, F ;
Emeriau, JP ;
Hanania, G .
EUROPEAN HEART JOURNAL, 2000, 21 (09) :763-769
[5]
The hemodynamic and neurohonnonal effects of low doses of tezosentan (an endothelih A/B receptor antagonist) in patients with acute heart failure [J].
Cotter, G ;
Kaluski, E ;
Stangl, K ;
Pacher, R ;
Richter, C ;
Milo-Cotter, O ;
Perchenet, L ;
Kobrin, I ;
Kaplan, S ;
Rainisio, M ;
Frey, A ;
Neuhart, E ;
Vered, Z ;
Dingemanse, J ;
Torre-Amione, G .
EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (05) :601-609
[6]
Role of cardiac power in heart failure [J].
Cotter, G ;
Williams, SG ;
Vered, Z ;
Tan, LB .
CURRENT OPINION IN CARDIOLOGY, 2003, 18 (03) :215-222
[7]
Acute heart failure: a novel approach to its pathogenesis and treatment [J].
Cotter, G ;
Moshkovitz, Y ;
Milovanov, O ;
Salah, A ;
Blatt, A ;
Krakover, R ;
Vered, Z ;
Kaluski, E .
EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (03) :227-234
[8]
Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry [J].
Fincke, R ;
Hochman, JS ;
Lowe, AM ;
Menon, V ;
Slater, JN ;
Webb, JG ;
LeJemtel, TH ;
Cotter, G .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (02) :340-348
[9]
Fonarow Gregg C, 2003, Rev Cardiovasc Med, V4 Suppl 7, pS21
[10]
GATTIS WA, 2003, J AM COLL CARDIOL S4, V17, P694